CVS Health goes into the biosimilar market with new subsidiary

CVS Health an­nounced Wednes­day that it launched a busi­ness that will work with drug­mak­ers to com­mer­cial­ize and man­u­fac­ture biosim­i­lars in the US, start­ing with a Hu­mi­ra biosim­i­lar de­vel­oped by San­doz.

San­doz has said it plans to launch Hy­ri­moz in Sep­tem­ber, and now the biosim­i­lar will al­so be made avail­able in the first quar­ter of 2024 un­der the pri­vate la­bel for Cor­davis, the new CVS sub­sidiary. CVS said it ex­pects the biosim­i­lar to cost 80% less than the cur­rent list price for Hu­mi­ra, Ab­b­Vie’s block­buster ther­a­py that lost patent ex­clu­siv­i­ty this year. GoodRx lists the price for two pens of Hu­mi­ra be­tween $6,000 and $7,000 at var­i­ous re­tail­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.